Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Brain Research

• Publication date

  2008-09-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.brainres.2008.06.124PMID 18657529PMCID PMC2585053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cerebral Cortical Arteriolar Angiopathy, Vascular Beta-Amyloid, Smooth Muscle Actin, Braak Stage, and APOE Genotype

  2008cited by this paper
• The blood-brain barrier in health and chronic neurodegenerative disorders.

  2008cited by this paper
• Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

  2007cited by this paper
• Pathogenesis of Alzheimer’s disease

  2007cited by this paper
• Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

  2007cited by this paper
• S100B and S100A6 Differentially Modulate Cell Survival by Interacting with Distinct RAGE (Receptor for Advanced Glycation End Products) Immunoglobulin Domains*

  2007cited by this paper
• A hundred years of Alzheimer's disease research.

  2006cited by this paper
• Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

  2006cited by this paper
• RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease

  2006influential reference
• P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model.

  2005cited by this paper
• RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain

  2003influential reference
• Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis.

  2003cited by this paper
• The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type.

  2002cited by this paper
• The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type

  2001cited by this paper
• Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.

  2001cited by this paper
• Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein

  2000cited by this paper
• Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

  2000cited by this paper
• Reduction of Lipofuscin-like Autofluorescence in Fluorescently Labeled Tissue

  1999influential reference
• Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier.

  1999cited by this paper
• The pathogenesis of Alzheimer's disease.

  1998cited by this paper
• Biology of A Amyloid in Alzheimer's Disease

  1997cited by this paper
• Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease.

  1997cited by this paper
• Function and Dysfunction in the Nervous System, Vol. 61. Cold Spring Harbor Symposia on Quantitative Biology

  1997cited by this paper
• Light microscopic image analysis system to quantify immunoreactive terminal area apposed to nerve cells.

  1997cited by this paper
• Biology of A beta amyloid in Alzheimer's disease.

  1997cited by this paper
• RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease

  1996cited by this paper
• RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.

  1996cited by this paper
• Advanced glycation end products contribute to amyloidosis in Alzheimer disease.

  1994cited by this paper
• Blood-brain barrier transport of circulating Alzheimer's amyloid beta.

  1993influential reference
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Hepatic aging as an etiological factor in the development of Alzheimer's disease.

  1990cited by this paper
• Expression of β-amyloid precursor protein in reactive astrocytes following neuronal damage

  1989cited by this paper
• Expression of beta-amyloid precursor protein in reactive astrocytes following neuronal damage.

  1989cited by this paper
• Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels.

  1985cited by this paper

• Brain capillary endothelial-like cells show altered barrier functionality and reduced transport of amyloid β in late-onset Alzheimer disease

  2026cites this paper
• Deep learning identifies TP-41 for methylglyoxal scavenging in Alzheimer's treatment

  2026cites this paper
• Pathology-directed drug delivery strategies: How to overcome blood–brain barrier for the treatment of brain diseases

  2025cites this paper
• Butyrate regulates the blood-brain barrier transport and intra-endothelial accumulation of Alzheimer’s disease Amyloid-beta peptides

  2025cites this paper
• Current Evidence on the Involvement of RAGE–Diaph1 Signaling in the Pathology and Treatment of Neurodegenerative Diseases—An Overview

  2025cites this paper
• RAGE-Mediated Effects of Formaldehyde in Alzheimer’s Disease

  2025cites this paper
• Glycogen synthase kinase-3 activation and dysregulation of amyloid transport receptors expression and shedding in HIV-induced Alzheimer’s disease-like pathology: modulatory effects of CCR5 antagonists

  2025cites this paper
• Type 3 Diabetes: A Molecular Link Between Cerebral Insulin Resistance and Neurodegeneration via AGE–RAGE Signaling

  2025cites this paper
• High-Density Lipoprotein Mimetic Peptide 4F Reduces Toxic Amyloid-Beta Exposure to the Blood-Brain Barrier Endothelium in Alzheimer's Disease Transgenic Mice.

  2024cites this paper
• Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs

  2024cites this paper
• Transient Receptor Potential Channels in the Healthy and Diseased Blood–Brain Barrier

  2024cites this paper
• Innate immune activation in neurodegenerative diseases.

  2024cites this paper
• Dl-3-n-butylphthalide promotes microglial phagocytosis and inhibits microglial inflammation via regulating AGE-RAGE pathway in APP/PS1 mice.

  2024cites this paper
• Challenges and Future Perspectives in Modeling Neurodegenerative Diseases Using Organ‐on‐a‐Chip Technology

  2024cites this paper
• Molecular dynamics of amyloid-β transport in Alzheimer's disease: Exploring therapeutic plasma exchange with albumin replacement - Current insights and future perspectives.

  2024cites this paper
• GLP-1/Sigma/RAGE Receptors: An evolving picture of Alzheimer's Disease pathology and treatment.

  2023cites this paper
• Unveiling new secrets in Parkinson's disease: the glycatome.

  2023cites this paper
• Local perfusion of capillaries reveals disrupted beta-amyloid homeostasis at the blood-brain barrier in Tg2576 murine Alzheimer’s model

  2023cites this paper
• Human isogenic cells of the neurovascular unit exert transcriptomic cell type-specific effects on a blood-brain barrier in vitro model of late-onset Alzheimer disease

  2023cites this paper
• Novel Therapeutic Opportunities for Neurodegenerative Diseases with Mesenchymal Stem Cells: The Focus on Modulating the Blood-Brain Barrier

  2023cites this paper
• The effect of NAC and Carnosine on alzheimer’s disease-related in vitro model through RAGE-AGE signaling pathway

  2023cites this paper
• IL-34 exacerbates pathogenic features of Alzheimer’s disease and calvaria osteolysis in triple transgenic (3x-Tg) female mice

  2023cites this paper
• Druggable targets for the immunopathy of Alzheimer's disease.

  2023cites this paper
• Reconsidering the role of blood-brain barrier in Alzheimer’s disease: From delivery to target

  2023cites this paper
• Endothelial Dysfunction in Neurodegenerative Diseases

  2023cites this paper
• Interaction of RAGE with α-synuclein fibrils mediates inflammatory response of microglia.

  2022cites this paper
• Dioscin alleviates Alzheimer's disease through regulating RAGE/NOX4 mediated oxidative stress and inflammation.

  2022cites this paper
• Vascular endothelial cells: a fundamental approach for brain waste clearance.

  2022cites this paper
• Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer’s Disease

  2022cites this paper
• Role of caspases, apoptosis and additional factors in pathology of Alzheimer's disease

  2022cites this paper
• Role and therapeutic potential of RAGE signaling in neurodegeneration.

  2022cites this paper
• Recent Treatment Strategies in Alzheimer’s Disease and Chronic Traumatic Encephalopathy

  2022cites this paper
• Biologically Active Fragment of the Receptor for Advanced Glycation End Products (RAGE) Is Able to Inhibit Oligomerization of the Beta-Amyloid

  2022cites this paper
• Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer's disease.

  2022cites this paper
• Contribution of hyperglycemia-induced changes in microglia to Alzheimer’s disease pathology

  2022cites this paper
• Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives

  2022cites this paper
• The effect of chronic stress and its preconditioning on spatial memory as well as hippocampal LRP1 and RAGE expression in a streptozotocin-induced rat model of Alzheimer’s disease

  2022cites this paper
• Multifaceted neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) in Alzheimer’s disease: an overview of pre-clinical studies focused on β-amyloid peptide

  2022cites this paper
• A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model

  2022cites this paper
• Receptors for Advanced Glycation End Products (RAGE): Promising Targets Aiming at the Treatment of Neurodegenerative Conditions

  2022cites this paper
• Models of cerebral amyloid angiopathy-related intracerebral hemorrhage

  2022cites this paper
• TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target

  2022cites this paper
• Ependymal cells and neurodegenerative disease: outcomes of compromised ependymal barrier function

  2022cites this paper
• Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice

  2021cites this paper
• Pathology, Risk Factors, and Oxidative Damage Related to Type 2 Diabetes-Mediated Alzheimer's Disease and the Rescuing Effects of the Potent Antioxidant Anthocyanin

  2021cites this paper
• Alzheimer's disease pathology is associated with earlier alterations to blood–brain barrier water permeability compared with healthy ageing in TgF344‐AD rats

  2021cites this paper
• Alzheimer’s disease: a step closer to understanding type 3 diabetes in African Americans

  2021cites this paper
• Advanced Human BBB‐on‐a‐Chip: A New Platform for Alzheimer's Disease Studies

  2021cites this paper
• Assessment of the Level of Rage in Cells Blood-Brain Barrier in Experimental Alzheimer’s Disease

  2021cites this paper
• Understanding the Role of Protein Glycation in the Amyloid Aggregation Process

  2021influential citation
• Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β‐amyloid peptide accumulation in mice

  2021cites this paper
• Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer’s disease by meta-analysis and adaptive boosting ensemble learning

  2021cites this paper
• Assessment of the Level of Rage in Cells Blood-Brain Barrier in Experimental Alzheimer’s Disease

  2021cites this paper
• Alzheimer: A Complex Genetic Background

  2021cites this paper
• Chinese Herbal Medicine Adjusting Brain Microenvironment via Mediating Central Nervous System Lymphatic Drainage in Alzheimer’s Disease

  2021cites this paper
• Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium.

  2021cites this paper
• Protective Effect of Ginkgolide B against Cognitive Impairment in Mice via Regulation of Gut Microbiota.

  2021cites this paper
• Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery

  2021cites this paper
• Hypercholesterolemia and 27-Hydroxycholesterol Increase S100A8 and RAGE Expression in the Brain: a Link Between Cholesterol, Alarmins, and Neurodegeneration

  2021cites this paper
• Blood–Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia

  2021cites this paper
• Interplay between brain pericytes and endothelial cells in dementia.

  2021cites this paper
• Elucidating the influence of environmentally relevant toxic metal mixture on molecular mechanisms involved in the development of neurodegenerative diseases: in silico toxicogenomic data-mining.

  2021cites this paper
• Cerebrovascular phenotypes in mouse models of Alzheimer’s disease

  2021cites this paper
• Dysregulated Wnt Signalling in the Alzheimer’s Brain

  2020cites this paper
• Plasma amyloid beta level changes in aged mice with cognitive dysfunction following sevoflurane exposure.

  2020cites this paper
• Vascular Component of Neuroinflammation in Experimental Alzheimer’s Disease in Mice

  2020cites this paper
• G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer’s disease pathology

  2020cites this paper
• Receptor for advanced glycation end products up‐regulation in cerebral endothelial cells mediates cerebrovascular‐related amyloid β accumulation after Porphyromonas gingivalis infection

  2020cites this paper
• Radiolabeling of [11C]FPS-ZM1, a receptor for advanced glycation end products-targeting positron emission tomography radiotracer, using a [11C]CO2-to-[11C]CO chemical conversion.

  2020cites this paper
• Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting

  2020cites this paper
• The biological pathways of Alzheimer disease: a review

  2020cites this paper
• Deterioration of cognitive function after transient cerebral ischemia with amyloid-β infusion—possible amelioration of cognitive function by AT2 receptor activation

  2020cites this paper
• Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

  2020cites this paper
• Neurovascular Unit Dysfunction and Neurodegenerative Disorders

  2020cites this paper
• Contributions of Drug Transporters to Blood-Brain Barriers.

  2019cites this paper
• Study on the influence of G82S RAGE polymorphism on RAGE-Amyloid interaction in AD pathology

  2019cites this paper
• AGE–RAGE stress: a changing landscape in pathology and treatment of Alzheimer’s disease

  2019cites this paper
• Crucial players in Alzheimer's disease and diabetes mellitus: Friends or foes?

  2019cites this paper
• Blood-Brain Barrier: From Physiology to Disease and Back.

  2019cites this paper
• The role of neurovascular unit damage in the occurrence and development of Alzheimer’s disease

  2019cites this paper
• Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer’s disease

  2019cites this paper
• Selective loss of cortical endothelial tight junction proteins during Alzheimer’s disease progression

  2019cites this paper
• Blood–Brain Barrier in Alzheimer's Disease

  2019cites this paper
• Molecular Bases of Alzheimer’s Disease and Neurodegeneration: The Role of Neuroglia

  2018cites this paper
• Metabolic Derangements Contribute to Reduced sRAGE Isoforms in Subjects with Alzheimer's Disease

  2018cites this paper
• RAGE-TLR Crosstalk Sustains Chronic Inflammation in Neurodegeneration

  2018cites this paper
• RAGE mediates A&bgr; accumulation in a mouse model of Alzheimer’s disease via modulation of &bgr;- and &ggr;-secretase activity

  2018cites this paper
• Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders

  2018cites this paper
• Chronic Arsenic Exposure Increases Aβ(1-42) Production and Receptor for Advanced Glycation End Products Expression in Rat Brain.

  2018cites this paper
• Effets de l’administration de tétrahydrobioptérine en condition physiologique et pathologique : De la neurobiologie au comportement

  2018cites this paper
• New Insights Into Autophagy Dysfunction Related to Amyloid Beta Toxicity and Neuropathology in Alzheimer's Disease.

  2018cites this paper
• A single high‐fat meal alters human soluble RAGE profiles and PBMC RAGE expression with no effect of prior aerobic exercise

  2018cites this paper
• Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration

  2017influential citation
• Activation of AMPK is neuroprotective in the oxidative stress by advanced glycosylation end products in human neural stem cells

  2017cites this paper
• Adiponectin controls the apoptosis and the expression of tight junction proteins in brain endothelial cells through AdipoR1 under beta amyloid toxicity

  2017cites this paper
• Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease

  2017cites this paper
• Blood-Brain Barriers in Obesity

  2017cites this paper
• Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease.

  2017cites this paper
• Vitamin C, Aging and Alzheimer’s Disease

  2017cites this paper
• Energy and the Alzheimer brain

  2017cites this paper